18. Lartruvo

FDA sign

Active ingredient: olaratumab
Disease: certain types of soft tissue sarcoma
Peak sales estimate: n/a
Approved: Oct. 19
Company: Eli Lilly

The scoop: En route to its accelerated approval in October, Eli Lilly’s olaratumab seemed to rack up every possible shortcut from the FDAfast-track and breakthrough therapy designations as well as priority review and orphan drug designation. The agency OK’d the drug as a first-line treatment for soft tissue sarcoma, to be used in tandem with doxorubicin. Soft tissue sarcoma encompasses a range of tumors that occur in the muscle, fat, blood vessels, nerves, tendons or the lining of the joints. Lartruvo works by blocking platelet-derived growth factor (PDGF) receptors, which may help or delay tumor growth. The Lartruvo-doxorubicin combo is indicated for patients whose STS cannot be cured by radiation or surgery. Their disease must also be a type where an anthracycline is an appropriate treatment. Lartruvo is the first new drug to be approved as an initial treatment for STS in four decades. Meanwhile, Johnson & Johnson’s Yondelis earned its long-awaited FDA nod a year prior for the treatment of two types of STS that affect smooth muscle and fat cells. -- Amirah Al Idrus

18. Lartruvo

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.